Efficacy and Safety of Trastuzumab as a Single Agent in First-Line

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line trastuzumab CONCLUSION: Administering higher doses on a 3-weekly schedule did not compromise the efficacy and safety of trastuzumab in women with HER2-positive MBC, and trastuzumab Trastuzumab deruxtecan provides durable benefits to patients with heavily pretreated HER2

trastuzumab Trastuzumab deruxtecan Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal

trastuzumab trastuzumab emtansine continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients 1 ยาพุ่งเป้า HER2 ที่ตัวรับ HER2 ที่ผิวเซลล์มะเร็ง แบ่งเป็น 2 ชนิด · Monoclonal antibody ออกฤทธิ์นอกเซลล์ ได้แก่ pertuzumab, trastuzumab (